Recently, Jilani et al. designed TYRP1+ CAR T-cell therapy to target cutaneous and rare melanoma subtypes . These CAR T-cells target the CD28 and CD19 receptors overexpressed on the surface of the melanoma cells . We hypothesize that the receptor binds to a specific orientation to form a strong interaction. In this work, molecular docking and molecular dynamics simulations were performed to study the mechanism of CD19 and CD28 receptors' interaction with the TYRP receptor. It was found that CD19-TYRP1 and CD28-TYRP1 lock each other and enhance the stability of the complex formed. The molecular docking binding site and the druggable site predicted by the graph neural network agreed to validate these results. The current research work will help design novel CAR T cells against melanoma.